Abstract Number: PB0051
Meeting: ISTH 2022 Congress
Background: The incidence of venous thromboembolism (VTE) in patients with COVID-19 during hospitalization and in the post-discharge setting has been reported with wide variability. Many studies have short follow-up, reported the early phase of the pandemic, or did not report bleeding or anticoagulant dosing.
Aims: We determined the incidence of symptomatic VTE and bleeding in patients admitted to hospital for COVID-19 and their 3-month risk of VTE post-discharge.
Methods: All patients admitted for COVID-19 at 5 regional hospitals were identified between January 1 and December 31, 2020. Data were collected from their hospital admission and for a minimum of 3 months post-discharge. Re-admissions during this period were considered as post-discharge data of the index admission. Standard thromboprophylaxis for critical care and ward patients were enoxaparin 30 mg twice daily or 40 mg once daily. Post-discharge thromboprophylaxis was not given. Patient consent was waived by the institutional research ethics board.
Results: A total of 565 patients were included. Baseline demographics are reported in Table 1. Median length-of-stay was 9.0 days (range 5-131). 178 patients (31.5%) required critical care support and 79 patients (14%) died during index admission. 25 patients (4.4%) had VTE during hospitalization, of which 17 occurred within first two weeks and none occurred in those on therapeutic anticoagulation. There were no fatal bleeds. 5 patients (0.88%) developed critical site bleeding. Patient characteristics, anticoagulant use and bleeding rates during hospitalization are reported in Table 2. Among 486 discharged patients, median length of follow-up was 163 days (range 3-600): 63.5% had at least 90 days of follow-up data and 18.7% were lost to follow-up. 5 patients (1.3%) had symptomatic VTE diagnosed within 3 months after discharge.
Conclusion(s): The in-hospital incidence of VTE in COVID-19 was lower but post-discharge incidence was higher than other studies. Therapeutic anticoagulation appeared protective against symptomatic VTE.
To cite this abstract in AMA style:Drury C, Lai C, Misselbrook G, Al Zaki A, Bhangu G, Conroy M, Eadie L, Kumar D, Li C, Manhas D, Singh N, Yuan J, Lee A, Wan T. A Multicenter Cohort Study of COVID-19 Associated Venous Thromboembolism in Admitted Patients Followed Longitudinally 3-Months After Discharge [abstract]. https://abstracts.isth.org/abstract/a-multicenter-cohort-study-of-covid-19-associated-venous-thromboembolism-in-admitted-patients-followed-longitudinally-3-months-after-discharge/. Accessed September 29, 2023.
« Back to ISTH 2022 Congress
ISTH Congress Abstracts - https://abstracts.isth.org/abstract/a-multicenter-cohort-study-of-covid-19-associated-venous-thromboembolism-in-admitted-patients-followed-longitudinally-3-months-after-discharge/